1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt hydrate
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:
LCMS, FT-IR, HPLC
Off-white to light yellow crystalline powder
+95.0° - +105.0° (c=1, MeOH)
Store long-term at 2-8°C
HAZARDOUS MATERIALS INFORMATION
Not hazardous material
DMSO: =8 mg/mL at 60 °C
Receptor antagonist (LTRA)
REVIEW Montelukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Montelukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.